Evidence map›Paper›PMID 11486024›Full record

ArticleMolecular and cellular biology2001

Role of phosphoinositide 3-kinase in the aggressive tumor growth of HT1080 human fibrosarcoma cells.

S Gupta, S Stuffrein, R Plattner, M Tencati, C Gray, Y E Whang, E J Stanbridge

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 24 citations in OpenAlex.

  1. Loss of the fructose transporter SLC2A5 inhibits cancer cell migration.Frontiers in cell and developmental biology · 2022
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Critical regulation of genes for tumor cell migration by AP-1.Clinical & experimental metastasis · 2004
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

S GuptaDepartment of Microbiology and Molecular Genetics, College of Medicine, University of California-Irvine, Irvine, CA 92697-4025, USA.
S Stuffrein
R Plattner
M Tencati
C Gray
Y E Whang
E J Stanbridge
University of California, Irvine · USUniversity of North Carolina at Chapel Hill · US

Funding

FUNCTIONAL ANALYSIS OF PTEN IN PROSTATE CANCERK08CA085772 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI WHANG, YOUNG E · 2000 to 2005
$651k
EVALUATION OF DOMINANTLY-ACTING RAS ONCOGENESR01CA069515 · NCI · UNIVERSITY OF CALIFORNIA IRVINE · PI STANBRIDGE, ERIC J. · 1996 to 2001
$345k
NCI NIH HHS CA69515NCI NIH HHS CA85772NCI NIH HHS K08 CA085772
6 · The paper itself

Abstract

We have developed a model system of human fibrosarcoma cell lines that do or do not possess and express an oncogenic mutant allele of N-ras. HT1080 cells contain an endogenous mutant allele of N-ras, whereas the derivative MCH603 cell line contains only wild-type N-ras. In an earlier study (S. Gupta et al., Mol. Cell. Biol. 20:9294-9306, 2000), we had shown that HT1080 cells produce rapidly growing, aggressive tumors in athymic nude mice, whereas MCH603 cells produced more slowly growing tumors and was termed weakly tumorigenic. An extensive analysis of the Ras signaling pathways (Raf, Rac1, and RhoA) provided evidence for a potential novel pathway that was critical for the aggressive tumorigenic phenotype and could be activated by elevated levels of constitutively active MEK. In this study we examined the role of phosphoinositide 3-kinase (PI 3-kinase) in the regulation of the transformed and aggressive tumorigenic phenotypes expressed in HT1080 cells. Both HT1080 (mutant N-ras) and MCH603 (wild-type N-ras) have similar levels of constitutively active Akt, a downstream target of activated PI 3-kinase. We find that both cell lines constitutively express platelet-derived growth factor (PDGF) and PDGF receptors. Transfection with tumor suppressor PTEN cDNA into HT1080 and constitutively active PI 3-kinase-CAAX cDNA into MCH603 cells, respectively, resulted in several interesting and novel observations. Activation of the PI 3-kinase/Akt pathway, including NF-kappaB, is not required for the aggressive tumorigenic phenotype in HT1080 cells. Activation of NF-kappaB is complex: in MCH603 cells it is mediated by Akt, whereas in HT1080 cells activation also involves other pathway(s) that are activated by mutant Ras. A threshold level of activation of PI 3-kinase is required in MCH603 cells before stimulatory cross talk to the RhoA, Rac1, and Raf pathways occurs, without a corresponding activation of Ras. The increased levels of activation seen were similar to those observed in HT1080 cells, except for Raf and MEK, which were more active than HT1080 levels. This cross talk results in conversion to the aggressive tumorigenic phenotype. This latter observation is consistent with our previous observation that overstimulation of the activity of endogenous members of Ras signaling pathways, activated MEK in particular, is a prerequisite for aggressive tumorigenic growth.

Indexed as

I-kappa B ProteinsProtein Serine-Threonine KinasesActinsAnimalsbcl-Associated Death ProteinCarrier ProteinsDNA-Binding ProteinsFibrosarcomaHumansMiceMice, NudeNF-kappa BNF-KappaB Inhibitor alphaPhosphatidylinositol 3-KinasesPhosphorylationPlatelet-Derived Growth FactorActinsAKT1 protein, humanBAD protein, humanBad protein, mousebcl-Associated Death ProteinCarrier ProteinsDNA-Binding ProteinsI-kappa B ProteinsNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanNfkbia protein, mousePhosphatidylinositol 3-KinasesPlatelet-Derived Growth Factorplatelet-derived growth factor AProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-sis

Identifiers

PMID11486024
PMCPMC87304
OpenAlexW2031856282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.